OncoMatch/Clinical Trials/NCT06584032
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Is NCT06584032 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including sintilimab and fruquintinib for advanced endometrial cancer.
Treatment: fruquintinib · sintilimab · paclitaxel · doxorubicin — The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Patients who previously failed first-line systemic platinum-based therapy
Cannot have received: anti-PD-1 therapy
Previously received any anti-programmed cell death receptor-1 (PD-1) antibody
Cannot have received: anti-PD-L1 therapy
Previously received any...anti-PD-L1(programmed death ligand-1) antibody
Cannot have received: anti-PD-L2 therapy
Previously received any...anti-PD-L2(programmed death ligand-2) antibody
Cannot have received: anti-CTLA-4 therapy
Previously received any...anti cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody
Cannot have received: checkpoint inhibitor
any other antibody acting on T cell costimulation or checkpoint pathways (eg, OX40, CD137, etc)
Cannot have received: VEGFR inhibitor
small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Lab requirements
Blood counts
Adequate function of the major organs
Kidney function
Adequate function of the major organs
Liver function
Adequate function of the major organs
Adequate function of the major organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify